Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant

This study is currently recruiting participants.
Verified November 2013 by Children's Oncology Group
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Children's Oncology Group
ClinicalTrials.gov Identifier:
NCT01817075
First received: March 20, 2013
Last updated: November 14, 2013
Last verified: November 2013
  Purpose

This randomized phase III trial studies chlorhexidine gluconate cleansing to see how well it works compared to control cleansing in preventing central line associated bloodstream infection and acquisition of multi-drug resistant organisms in younger patients with cancer or undergoing donor stem cell transplant. Chlorhexidine gluconate may help reduce bloodstream infections and bacterial infections associated with the central line


Condition Intervention Phase
Bacterial Infection
Infection
Neoplasm
Methicillin-resistant Staphylococcus Aureus Infection
Drug: chlorhexidine gluconate
Procedure: wound care management
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Prevention
Official Title: Impact of Cleansing With Chlorhexidine Gluconate (CHG) on Reducing Central Line Associated Bloodstream Infection (CLABSI) and Acquisition of Multi-Drug Resistant Organisms (MDRO) in Children With Cancer or Those Receiving Allogeneic Hematopoietic Cell Transplantation (HCT)

Resource links provided by NLM:


Further study details as provided by Children's Oncology Group:

Primary Outcome Measures:
  • Number of CLABSI events during the at-risk days [ Time Frame: Up to 90 days ] [ Designated as safety issue: No ]
    Estimated and compared between the 2 arms by a Poisson regression model adjusting for the randomization stratification factor on treatment/diagnosis.


Secondary Outcome Measures:
  • Acquisition of MDRO [ Time Frame: Up to 90 days ] [ Designated as safety issue: No ]
    Compared between the two arms using logistic regression. Non-linear mixed effects models will also be used to examine the effect of CHG on the proportion of patients acquiring MDRO with adjustment for the treating institution as random effects.

  • Susceptibility to CHG as measured by minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs) [ Time Frame: Up to 90 days ] [ Designated as safety issue: No ]
    Compared between the two arms using logistic regression. Nonlinear mixed models applied to explore the association between CHG cleansing and reduced susceptibility to CHG over the longitudinal assessments.

  • Number of bacteremia episodes during the at-risk days [ Time Frame: Up to 90 days ] [ Designated as safety issue: No ]
    Poisson regression model used for detecting the reduction in the rate of bacteremia at 2-sided alpha level of 0.05.


Estimated Enrollment: 450
Study Start Date: June 2013
Estimated Primary Completion Date: January 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm I (CHG cleansing wipe)
Patients receive chlorhexidine gluconate cleansing with topical skin wipes QD for 90 days. Cloths impregnated with 2% CHG. Once daily. Wound care management as necessary.
Drug: chlorhexidine gluconate
Receive CGH cleansing with cloths impregnated with 2% CHG once daily.
Other Names:
  • Chlorhexidine Gluconate cloth 2%
  • NSC #753971
Procedure: wound care management
Receive control cleansing
Active Comparator: Arm II (control)
Patients receive control cleansing with topical skin wipes QD for 90 days. Cloths impregnated with mild soap and moisturizers. Once Daily. Wound care management as necessary.
Procedure: wound care management
Receive control cleansing

Detailed Description:

PRIMARY OBJECTIVES: I. To determine whether chlorhexidine gluconate (CHG) cleansing decreases central line associated bloodstream infection (CLABSI) in children with cancer or those receiving an allogeneic hematopoietic cell transplantation (HCT). SECONDARY OBJECTIVES: I. To determine whether CHG cleansing decreases acquisition of multi-drug resistant organisms [MDRO: vancomycin resistant enterococci (VRE), methicillin resistant Staphylococcus aureus (MRSA), etc.] in children with cancer or those receiving allogeneic HCT. II. To determine whether CHG cleansing in children with cancer or those receiving allogeneic HCT is associated with cutaneous bacterial isolates with reduced susceptibility to CHG. III. To determine whether CHG cleansing decreases positive blood cultures in children with cancer or those receiving allogeneic HCT. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients receive CHG cleansing with topical skin wipes once daily (QD) for 90 days. ARM II: Patients receive control cleansing with topical skin wipes QD for 90 days.

  Eligibility

Ages Eligible for Study:   2 Months to 21 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • All patients undergoing planned allogeneic transplant (both malignant and non-malignant diagnoses)
  • Patients with an oncology diagnosis that are on a chemotherapy regimen that will last for an additional >= 3 months; patients with an oncology diagnosis that will be on a chemotherapy regimen for >= 3 months
  • Patients must have, or be scheduled to have, an external tunneled central venous catheter (CVC) (Broviacs, Hickmans, tunneled percutaneously inserted central catheter (PICCs), etc.) that is expected to remain in place for an additional >= 3 months

Exclusion Criteria:

  • Patients with a previous or current line infection are ineligible until 14 days after the completion of antibiotics
  • Subjects who would enroll in the Oncology Patient stratum who are planned to start conditioning for HCT within 3 months of enrollment are ineligible
  • Patients with only non-tunneled CVCs (non-tunneled peripherally inserted central catheters [PICCs], temporary CVCs, midline catheters, etc) are ineligible
  • Patients with only totally implanted CVCs or ports are ineligible
  • Patients with a known allergy or hypersensitivity to CHG are ineligible
  • Patients with chronic, severe, generalized skin breakdown (such as generalized blistering, burns, severe graft versus host disease [GVHD] with open sores, etc.) are ineligible
  • Patients enrolled on ACCL0934 are ineligible
  • Patients scheduled to receive broad-spectrum prophylactic antibacterial therapy are ineligible
  • Patients receiving sorafenib at the time of enrollment or as part of a treatment plan scheduled to receive sorafenib are ineligible
  • Patients using prophylactic antimicrobial locks in the CVC at the time of enrollment or as part of a treatment plan scheduled to receive prophylactic antimicrobial locks in the CVC are ineligible
  • Patients previously enrolled on this trial are ineligible
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01817075

Locations
United States, California
Children's Oncology Group Recruiting
Arcadia, California, United States, 91006-3776
Contact: Danielle M. Zerr    206-987-2653    danielle.zerr@seattlechildrens.org   
Principal Investigator: Danielle M. Zerr         
Sponsors and Collaborators
Children's Oncology Group
Investigators
Principal Investigator: Danielle Zerr Children's Oncology Group
  More Information

No publications provided

Responsible Party: Children's Oncology Group
ClinicalTrials.gov Identifier: NCT01817075     History of Changes
Other Study ID Numbers: ACCL1034, NCI-2013-00595, U10CA095861, COG-ACCL1034
Study First Received: March 20, 2013
Last Updated: November 14, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Bacterial Infections
Staphylococcal Infections
Gram-Positive Bacterial Infections
Neoplasms
Chlorhexidine
Chlorhexidine gluconate
Anti-Infective Agents, Local
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Disinfectants
Dermatologic Agents

ClinicalTrials.gov processed this record on April 16, 2014